Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

Multiple sclerosis An emerging therapeutic area for <strong>Roche</strong> • MS is a common neurological disease affecting more than 1 million people worldwide • Multifocal inflammatory disease that damages the myelin of CNS and causes neurological impairment and, frequently, severe disability • Commonest cause of neurological disability in young and middle-aged adults • Prevalence of MS varies by geographical areas – high prevalence: Europe, Northern US, Canada, AUS – low prevalence: Japan and Africa • More common in women (2:1), Caucasians MRI allows clinicians to detect and follow pathological progression of disease & response to treatment 66
Multiple sclerosis therapies and treatment trends Diagnosis and treatment rates for MS in major pharma markets 300 Prevalent population (thousands) 250 200 150 100 50 0 United States Source: Decision Resources Undiagnosed France Germany Italy Spain United Kingdom Japan Diagnosed, not drug-treated Diagnosed, drug-treated 67
Page 2 and 3:
Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5:
Introduction Dr. Karl Mahler Head o
Page 6 and 7:
Roche’s key therapeutic areas Cur
Page 8 and 9:
RA: A very concentrated market 6.00
Page 10 and 11:
Increased penetration of biologics
Page 12 and 13:
Actemra: The OPTION trial results P
Page 14 and 15:
Elevated IL-6 plays central role in
Page 16 and 17: The OPTION study TOcilizumab Pivota
Page 18 and 19: Demographics Intent-to-treat popula
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 52 and 53: Rates of serious infection Similar
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57: Overview of autoimmune disorders IN
Page 58 and 59: Not all patients respond to current
Page 60 and 61: Major players are active in this ar
Page 62 and 63: Actemra Potential to become a signi
Page 64 and 65: Ocrelizumab in autoimmune diseases
Page 68 and 69: Prevalence of MS in Europe ~260,000
Page 70 and 71: Development hurdles & treatment cha
Page 72 and 73: Roche in autoimmune disorders Roche
show all

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?